Anhui Huaren Health Pharmaceutical Co., Ltd.

SZSE:301408 Stock Report

Market Cap: CN¥4.9b

Anhui Huaren Health Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Anhui Huaren Health Pharmaceutical has been growing earnings at an average annual rate of 15.3%, while the Consumer Retailing industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 19.1% per year. Anhui Huaren Health Pharmaceutical's return on equity is 7.2%, and it has net margins of 3.1%.

Key information

15.3%

Earnings growth rate

11.7%

EPS growth rate

Consumer Retailing Industry Growth12.8%
Revenue growth rate19.1%
Return on equity7.2%
Net Margin3.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Anhui Huaren Health Pharmaceutical's (SZSE:301408) Weak Earnings May Only Reveal A Part Of The Whole Picture

May 07
Anhui Huaren Health Pharmaceutical's (SZSE:301408) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Anhui Huaren Health Pharmaceutical (SZSE:301408) Is Reinvesting At Lower Rates Of Return

Dec 12
Anhui Huaren Health Pharmaceutical (SZSE:301408) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Anhui Huaren Health Pharmaceutical (SZSE:301408) Is Using Debt Extensively

Aug 07
These 4 Measures Indicate That Anhui Huaren Health Pharmaceutical (SZSE:301408) Is Using Debt Extensively

Anhui Huaren Health Pharmaceutical's (SZSE:301408) Weak Earnings May Only Reveal A Part Of The Whole Picture

May 07
Anhui Huaren Health Pharmaceutical's (SZSE:301408) Weak Earnings May Only Reveal A Part Of The Whole Picture

Returns On Capital Signal Tricky Times Ahead For Anhui Huaren Health Pharmaceutical (SZSE:301408)

Mar 25
Returns On Capital Signal Tricky Times Ahead For Anhui Huaren Health Pharmaceutical (SZSE:301408)

Revenue & Expenses Breakdown

How Anhui Huaren Health Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301408 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,3881351,12836
30 Jun 244,2341291,06635
31 Mar 244,0561331,01628
31 Dec 233,79711596424
30 Sep 233,70318093011
30 Jun 233,5841778858
31 Mar 233,4311758516
01 Jan 233,2621618084
01 Jan 222,339706920
31 Dec 201,931895640
31 Dec 191,522524830
31 Dec 181,105203770

Quality Earnings: 301408 has high quality earnings.

Growing Profit Margin: 301408's current net profit margins (3.1%) are lower than last year (4.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301408's earnings have grown by 15.3% per year over the past 5 years.

Accelerating Growth: 301408's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301408 had negative earnings growth (-25.4%) over the past year, making it difficult to compare to the Consumer Retailing industry average (6%).


Return on Equity

High ROE: 301408's Return on Equity (7.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:33
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anhui Huaren Health Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution